Literature DB >> 3044649

Humoral immune responses within the lung of bone marrow transplant recipients studied by bronchoalveolar lavage.

H J Milburn1, J E Grundy, R M du Bois, H G Prentice, P D Griffiths.   

Abstract

We investigated 20 bone marrow transplant recipients with pneumonitis using bronchoalveolar lavage (BAL) to assess the humoral immune response in the lung. We measured the levels of total IgG, IgM and IgA in bronchoalveolar lavage fluid and serum, and albumin measurements were used to correct for simple diffusion of immunoglobulins from serum into the lung. We found evidence for the local production of immunoglobulins G, M and A in 15 patients. This was independent of the cause of the pneumonitis. We also found that, although seven patients who recovered from their pulmonary problem had evidence of considerable local production of immunoglobulin, eight patients who died were also producing immunoglobulins in the lung. Death due to pneumonitis in BMT recipients cannot, therefore, be ascribed to a failure of the local humoral immune response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044649      PMCID: PMC1541542     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Role of bronchoalveolar lavage in the evaluation of interstitial pneumonitis in recipients of bone marrow transplants.

Authors:  H J Milburn; H G Prentice; R M du Bois
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

2.  Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci.

Authors:  P D Griffiths; D D Panjwani; P R Stirk; M G Ball; M Ganczakowski; H A Blacklock; H G Prentice
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

3.  Assessment of 7S and 11S immunoglobulin A in sputum.

Authors:  R A Stockley; S C Afford; D Burnett
Journal:  Am Rev Respir Dis       Date:  1980-12

4.  A study of plasma proteins in the sol phase of sputum from patients with chronic bronchitis.

Authors:  R A Stockley; M Mistry; A R Bradwell; D Burnett
Journal:  Thorax       Date:  1979-12       Impact factor: 9.139

Review 5.  Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

Review 6.  Infectious complications of human bone marrow transplantation.

Authors:  D J Winston; R P Gale; D V Meyer; L S Young
Journal:  Medicine (Baltimore)       Date:  1979-01       Impact factor: 1.889

7.  Air-space immunoglobulin production and levels in bronchoalveolar lavage fluid of normal subjects and patients with sarcoidosis.

Authors:  J A Rankin; G P Naegel; C E Schrader; R A Matthay; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1983-04

8.  Variability in sputum sol phase proteins in chronic obstructive bronchitis. The value of using albumin for standardization.

Authors:  J Wiggins; R A Stockley
Journal:  Am Rev Respir Dis       Date:  1983-07

9.  T-lymphocyte subsets and immunoglobulin concentrations in bronchoalveolar lavage of patients with sarcoidosis and high and low intensity alveolitis.

Authors:  W Bauer; M K Gorny; H R Baumann; A Morell
Journal:  Am Rev Respir Dis       Date:  1985-11

10.  Alpha-2-macroglobulin, monomeric and polymeric immunoglobulin A, and immunoglobulin M in bronchoalveolar lavage.

Authors:  D L Delacroix; F X Marchandise; C Francis; Y Sibille
Journal:  Am Rev Respir Dis       Date:  1985-10
View more
  2 in total

1.  Pneumonitis in bone marrow transplant recipients results from a local immune response.

Authors:  H J Milburn; R M Du Bois; H G Prentice; L W Poulter
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

2.  Can lung function measurements be used to predict which patients will be at risk of developing interstitial pneumonitis after bone marrow transplantation?

Authors:  H J Milburn; H G Prentice; R M du Bois
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.